Eurobio Scientific Presented Breast Cancer Research at ESMO 2022

Eurobio Scientific provided insights into treatment decision-making for early-stage breast cancer at an industry satellite symposium held during the ESMO 2022 congress in September 2022.

The symposium focused on the application of the EndoPredict test, utilizing genetic signatures to inform chemotherapy decisions for ER+/HER2- premenopausal patients. Dr. Anastasia Constantinidou presented key data demonstrating how the test can guide therapeutic choices and help avoid overtreatment in this patient population.

The event aimed to share current research and advance the understanding of treatment strategies for early breast cancer. Eurobio Scientific hosted the symposium, which featured information on Myriad Genetics' offerings in this field.

Eurobio Scientific operates in the field of oncology diagnostics, providing solutions for cancer detection and treatment. The company is involved in advancing molecular diagnostics within the healthcare sector.

The presented information was medical in nature and targeted healthcare professionals involved in the care of breast cancer patients, with the goal of offering tools for more personalized treatment selection.